IP Library Granted Patent US 8,999,710
Granted Patent B2
US 8,999,710 · App. 13/816,909 · Granted Apr 7, 2015

Process for the preparation of disinfected human cell suspensions

Inventors: Krasimira Aleksandrova (Hannover, DE); Marc Barthold (Hannover, DE); Lubomir Arseniev (Hannover, DE); Carsten Griesel (Ladenburg, DE); Christoph Priesner (Hannover, DE)
Assignee: Cytonet GmbH & Co. KG
C12N5/067A01N1/0215C12N2501/70C12N2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,710
App. No.
13/816,909
Granted
Apr 7, 2015
Kind
B2
Abstract

In a process for preparing disinfected preparations from mammalian tissues, mammalian tissue is perfused at one step with an enzyme-free liquid antibiotic composition that includes at least one antibiotic and is contained in at least one perfusion buffer. In a step occurring after such one step, enzymatic antibiotic-free treatment of the tissue is carried out to obtain a single-cell suspension. In another step disinfected preparations are obtained.

Claims (10)

1. A process for preparing disinfected, single-cell suspension preparations from mammalian tissue, comprising:

prior to any enzymatic treatment of said mammalian tissue, performing a primary decontamination of a surface of the mammalian tissue comprising rinsing the mammalian tissue to obtain a rinsed mammalian tissue;

after said primary decontamination, perfusing said rinsed mammalian tissue with an enzyme-free liquid antibiotic composition that comprises at least one antibiotic and is contained in at least one perfusion buffer, wherein the enzyme-free liquid antibiotic composition is perfused through vascular tissue inherent to the mammalian tissue to obtain an antibiotic-treated mammalian tissue;

subsequent to all antibiotic perfusion, carrying out an enzymatic antibiotic-free treatment of the tissue to obtain the disinfected, single-cell suspension preparations comprising contacting said antibiotic-treated mammalian tissue with collagenase I and clostridiopeptidase I to obtain disinfected single-cell suspension preparations;

washing the obtained disinfected single-cell suspension preparations with an antibiotic-free washing buffer to obtain a washed disinfected single-cell suspension preparation;

subsequent to said washing step, and without an intervening antibiotic treatment, performing a microbiological sterility test of the washed disinfected single-cell suspension preparation; and

wherein said washing is adapted to either one of reduce or eliminate said antibiotic from said disinfected single-cell suspension so as not to have a negative effect on said microbiological sterility test.

2. The process according to claim 1 , wherein the tissue is liver tissue.

3. The process according to claim 1 , wherein a time duration of said perfusing is 30 to 120 min and wherein temperature of the enzyme-free liquid antibiotic composition is increased during the perfusion.

4. The process according to claim 1 , wherein the enzyme-free liquid antibiotic composition is contained in at least two perfusion buffers, at least one of the perfusion buffers being an EGTA- or EDTA-containing phosphate/HEPES buffer and at least one other of the buffers being a phosphate/HEPES buffer.

Assignments (3)
CHANGE OF NAME Recorded Jan 9, 2024
From: PROMETHERA THERAPEUTICS SA
To: CELLAÏON SA
Reel/Frame 066064/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2016
From: CYTONET GMBH & CO. KG.
To: PROMETHERA BIOSCIENCES SA
Reel/Frame 040436/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2013
From: ALEKSANDROVA, KRASIMIRA; BARTHOLD, MARC; ARSENIEV, LUBOMIR; GRIESEL, CARSTEN; PRIESNER, CHRISTOPH
To: CYTONET GMBH & CO. KG
Reel/Frame 030031/0302 →
Priority Claims (1)
DE 10 2010 034 330 · Aug 14, 2010 · national
Continuity (1)
Related Publication 20130143324A1 · Jun 6, 2013